0000950170-24-022413.txt : 20240228
0000950170-24-022413.hdr.sgml : 20240228
20240228182238
ACCESSION NUMBER: 0000950170-24-022413
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240226
FILED AS OF DATE: 20240228
DATE AS OF CHANGE: 20240228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cohen Joshua B
CENTRAL INDEX KEY: 0001898644
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 24697778
MAIL ADDRESS:
STREET 1: C/O AMYLYX PHARMACEUTICALS, INC.
STREET 2: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
ownership.xml
4
X0508
4
2024-02-26
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001898644
Cohen Joshua B
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02141
true
true
false
false
Co-Chief Executive Officer
false
Common Stock
2024-02-26
4
A
false
126667
0.00
A
3027137
D
Stock Option (right to buy)
17.56
2024-02-26
4
A
false
190000
0.00
A
2034-02-25
Common Stock
190000
190000
D
The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
/s/ Joshua B. Cohen
2024-02-28